Allan Kiprianos is a post-doctoral research associate in the department of Vascular Sciences, at the National Heart and Lung Institute, Hammersmith hospital. He graduated from the University of Westminster in 2004 (2i, BSc Physiology), followed by a PGCE from the University of Exeter (2005).
He moved to the University of Birmingham in 2005–06 where he studied towards an MRes in Molecular Toxicology. His thesis in the School of Biosciences, under the supervision of Dr. Rosemary Waring, focused on the protective role of exogenous flavonoids on models of Parkinson’s disease, looking at how antioxidants might confer protection against mitochondrial toxins.
In 2007 he moved to the University of Birmingham’s Medical School to undertake a PhD in rheumatology with Dr. Stephen Young and Prof. Paul Bacon in the Institute of Inflammation and Ageing. He completed his PhD in 2011 focusing on the role of the redox-sensitive enzyme acid sphingomyelinase (ASM) on endothelial dysfunction. Alongside his basic science research, he was responsible for the retrospective analysis of a multi-cohort study looking levels of ASM in patients with autoimmune chronic inflammatory diseases. These investigations reviewed the potential for serum-derived ASM to contribute to early endothelial damage, leading to disrupted vascular function, and accelerated atherosclerosis.
Following a post as a medical writer in the private sector, gaining experience on deliverables for clients in the pharmaceutical industry, he moved to Imperial College London in 2013 to lead on a NIHR-BRC Immunology funded project in the laboratory of Prof. Justin Mason. His clinical research reviews potential biomarkers in large vessel vasculitides, while his basic science work focuses on the interaction of soluble mediators with the endothelium under flow-shear stress. This work investigates the molecular alterations and signalling pathways involved in the vascular microenvironment under normal laminar, or perturbed blood flow.
Current work aims to link with clinical expertise in the department, to further understand the translational potential of the group’s research with outcomes from the clinic.
Research and outside interests include:
- Immune-endothelial crosstalk
- Lipid signalling
- Biomarker & risk identification targets
- Redox regulation of vascular function
- Extracellular vesicles
- Mechanisms of atherosclerosis
- Cardiovascular disease
- Translational medicine
- Public engagement
- Science communication
et al., 2016, A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet’s Syndrome, Clinical and Experimental Rheumatology, Vol:6, ISSN:1593-098X
et al., 2016, Identification of cyclins A1, E1 and vimentin as downstream targets of heme oxygenase-1 in vascular endothelial growth factor-mediated angiogenesis, Scientific Reports, Vol:6, ISSN:2045-2322
et al., 2014, Synergistic therapeutic vascular cytoprotection against complement- mediated injury induced via a PKC alpha-, AMPK-, and CREB- dependent pathway, Journal of Immunology, Vol:192, ISSN:1550-6606, Pages:4316-4327
et al., 2012, Elevated active secretory sphingomyelinase in antineutrophil cytoplasmic antibody-associated primary systemic vasculitis, Annals of the Rheumatic Diseases, Vol:71, ISSN:0003-4967, Pages:1100-1102
et al., 2016, A LOW BALANCE BETWEEN MICROPARTICLES EXPRESSING TISSUE FACTOR PATHWAY INHIBITOR AND TISSUE FACTOR IS ASSOCIATED WITH THROMBOSIS IN BEHCET'S SYNDROME, CLINICAL & EXPER RHEUMATOLOGY, Pages:S143-S143, ISSN:0392-856X